Nautilus Biotechnolgy
NAUT
93 hedge funds and large institutions have $93.7M invested in Nautilus Biotechnolgy in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 17 closing their positions.
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
15% more funds holding
Funds holding: 81 → 93 (+12)
3.48% less ownership
Funds ownership: 42.94% → 39.46% (-3.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
56% less capital invested
Capital invested by funds: $211M → $93.7M (-$117M)
59% less call options, than puts
Call options by funds: $38K | Put options by funds: $92K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.01M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.35M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.75M |
| 5 |
Barclays
London,
United Kingdom
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AH Capital Management
Menlo Park,
California
|
-$22.7M |
| 2 |
ACI
Amazon.com Inc
Seattle,
Washington
|
-$5.65M |
| 3 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$3.79M |
| 4 |
Millennium Management
New York
|
-$2.86M |
| 5 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$2.82M |
NAUT Hedge Fund Activity: Q2 2026 in Review
93 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q2 2026, worth a combined $93.7M — down 56% from $211M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new NAUT positions and 17 closed out — a net gain of 13 holders — while 29 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $6.6M. The largest seller was AH Capital Management, cutting an estimated $22.7M.
- 93 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $93.7M of Nautilus Biotechnolgy stock for Q2 2026, down 56% quarter-over-quarter.
- 30 funds opened new Nautilus Biotechnolgy positions in Q2 2026 and 17 closed out, a net change of +13 holders.
- The largest Nautilus Biotechnolgy buyer in Q2 2026 was BlackRock, an estimated $6.6M added.
- The largest Nautilus Biotechnolgy seller in Q2 2026 was AH Capital Management, an estimated $22.7M sold.
Based on aggregated 13F filings for Q2 2026.